Belite Bio (BLTE) Treasury Shares (2021 - 2025)

Belite Bio's (BLTE) quarterly Treasury Shares came in at $155751.0 in Q4 2025, down 98.01% quarter-over-quarter from $7.8 million in Q4 2021.

Belite Bio (BLTE) Treasury Shares (2021 - 2025) Analysis & Trends

Belite Bio's Treasury Shares history runs 2 years deep, the most recent figure standing at $155751.0 for Q4 2025.

On a quarterly basis, Treasury Shares changed N/A year-over-year to $155751.0 in Q4 2025; TTM through Dec 2025 was $155751.0, a N/A change from a year earlier, with the FY2025 full-year figure at $155751.0, changed N/A from the prior year.
Treasury Shares declined to $155751.0 in Q4 2025 per BLTE's latest filing, from $7.8 million in the prior quarter.
Across five years, Treasury Shares topped out at $7.8 million in Q4 2021 and bottomed at $155751.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-21,709.08
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	265,401.92
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	34.70 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	5.14 Mn
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn	-

Download Data